

Durvalumab

REJECTED

The Expert Committee, after evaluation, declines to list the medicine proposed in the application.
The Model List of Essential Medicines reports reasons that Committee Members have identified for denying listing.

General description

| | |
|----------------------------|--|
| INN | Durvalumab |
| ATC codes | L01FF03 |
| Medicine type | Biological agent |
| EML status history | Application rejected in 2023 (TRS 1049) for Other specified malignant neoplasms of bronchus or lung |
| Therapeutic equivalent for | |
| Wikipedia | Durvalumab ↗ |
| DrugBank | Durvalumab ↗ |

Recommendations

Section Immunomodulators

Parenteral > General injections > IV: 120 mg per 2.4 mL in vial; 500 mg per 10 mL in vial

Indications

Other specified malignant neoplasms of bronchus or lung

